Tandem Diabetes Care Announces Upcoming Conference Participation

TNDM 10.30.2024

Full Press ReleaseSEC FilingsOur TNDM Tweets

About Gravity Analytica

Recent News

  • 02.26.2025 - Tandem Diabetes Care Q4 2024 Earnings
  • 01.15.2025 - Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
  • 01.07.2025 - Tandem Diabetes Care Enters Multi-Year Research Collaboration with UVA Center for Diabetes Technology for Development of Advanced Insulin Delivery Systems

Recent Filings

  • 12.18.2024 - 4 Statement of changes in beneficial ownership of securities
  • 11.21.2024 - 144 Report of proposed sale of securities
PDF Version

SAN DIEGO--(BUSINESS WIRE)--Oct. 30, 2024--Tandem Diabetes Care, Inc.(Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will host meetings and present a company update at the following investor conferences:

  • UBS Global Healthcare ConferenceonThursday, November 14, 2024at11:45am Eastern Time(8:45am Pacific Time),
  • Stifel 2024 Healthcare Conference onTuesday, November 19, 2024at11:30am Eastern Time(8:30am Pacific Time),
  • Jefferies London Healthcare ConferenceonWednesday, November 20, 2024at4:30pm GMT(11:30am ET,8:30am PT), and
  • Wolfe Research Healthcare ConferenceonWednesday, November 20, 2024at8:40am Eastern Time(5:40am Pacific Time).

In addition, the Company will host meetings at the 2024 Canaccord Genuity MedTech, Diagnostics andDigital Health & Services ForumonThursday, November 21, 2024.

The presentations will be webcast live, and an archive recording will be available for 30 days. The link to the live webcasts and archive will be accessible on Tandem Diabetes Care’s Investor Center website located athttp://investor.tandemdiabetes.comin the “Events & Presentations” section.

AboutTandem Diabetes Care, Inc.

Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology.Tandem Diabetes Careis based inSan Diego, California. For more information, visittandemdiabetes.com.

Tandem Diabetes Care, the Tandem logo, Control-IQ, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks ofTandem Diabetes Care, Inc.inthe United Statesand/or other countries.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241030276890/en/

Media Contact:858-366-6900media@tandemdiabetes.com

Investor Contact:858-366-6900IR@tandemdiabetes.com

Source:Tandem Diabetes Care, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com